GlassScriptPhysician profile
Scott B Hunter
NPI 1316318447
$2,018.46
in general payments reported to CMS, 2019-2025
26 companies · $34.78 in 2025
The $34.78 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,304 · 2022: $531 · 2023: $149 · 2025: $34.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.91 | 2021-2023 | |
| Novo Nordisk INC | $309.45 | 2021-2022 | |
| Amgen INC. | $163.22 | 2021-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $140.09 | 2021-2022 | |
| Amarin Pharma, INC. | $121.14 | 2021 | |
| Abbott Laboratories | $110.05 | 2021-2023 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $107.34 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $104.67 | 2021-2022 | |
| Eisai INC. | $74.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $73.09 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.55 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.08 | 2021 | |
| Optinose US, INC. | $48.61 | 2021 | |
| Esperion Therapeutics, INC. | $43.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.06 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $34.78 | 2025 | Nimbl, Flexitouch Plus |
| Clarus Therapeutics INC. | $30.38 | 2021 | |
| Pfizer INC. | $24.82 | 2021 | |
| Kci USA, INC. | $22.85 | 2022 | |
| Astellas Pharma US INC | $17.55 | 2021 | |
| Aytu Biopharma, INC. | $17.31 | 2021 | |
| Dexcom, INC. | $15.77 | 2021 | |
| Opko Pharmaceuticals, LLC | $15.16 | 2021 | |
| Medtronic, INC. | $14.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.28 | 2021 | |
| Genentech USA, INC. | $10.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.